Joint Initiative, “Safe Anaesthesia – ASAP,” Is to Improve Anesthesia Care in Low Resource Countries
IRVINE, Calif. & HONG KONG - Tuesday, August 30th 2016 [ME NewsWire]
(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced Sunday at the World Congress of Anaesthesiologists (WCA) in Hong Kong that it has become the first Global Impact Partner of the World Federation of Societies of Anaesthesiologists (WFSA). The four-year partnership, “Safe Anaesthesia – ASAP” (Anesthesia Safety Action Plan), will initially identify one country with poor access to safe anesthesia, and will work toward implementing programs and training designed to improve anesthesia care and safe surgery outcomes.
In 2015, the Lancet Commission on Global Surgery reported that approximately 5 billion people – the majority of the world’s population – do not have access to safe, affordable anesthesia and surgical care, and estimated that 16.9 million die annually as a result.1 These deaths are attributable to a lack of infrastructure, essential monitoring equipment, and drugs, as well as a shortage of adequately trained healthcare workers.1
As part of the first phase of the joint project between the WFSA and Masimo, a high burden country will be identified as the ASAP’s focus. Key to the project’s success will be bringing together all stakeholders, including the government, so that infrastructure gaps can be identified, needs assessed, and the ASAP implemented. Implementation will involve a combination of training courses and other educational materials, distribution of essential drugs, and installation of and training on medical equipment. Training, monitoring, and project assessment will be ongoing throughout the four years, with an emphasis on ensuring that the improvements are sustainable.
Lifebox, an NGO (not-for-profit, non-governmental organization) dedicated to improving safe surgery, will also be assisting with training support. Kristine Stave, Chief Operating Officer of Lifebox, commented, “Lifebox works with colleagues on the front line of the global surgical safety crisis to support long-term improvement in the safety and quality of anesthesia care. We know firsthand the challenges of environment, equipment, education – and we also know the extraordinary capacity for positive change that the best partnerships can bring. We’re proud to be a part of this urgent and historic undertaking between the WFSA and Masimo, and to be delivering our shared goal of making anesthesia safer for millions of patients worldwide.”
WFSA has been uniting anesthesiologists globally for more than 60 years. With a network of hundreds of thousands of anesthesiologists in more than 150 countries, WFSA is well positioned to deliver programs that facilitate learning, and promote the highest standard of anesthesia care globally. Masimo, whose clinically leading SET® pulse oximetry is used to monitor over 100 million patients across the world, has made a commitment to become a WFSA Global Impact Partner in 2016. Together, WFSA and Masimo created the ASAP action plan, which it is hoped will become a model for high burden countries to improve anesthesia care and safe surgery outcomes.
Dr. David Wilkinson, President of the WFSA, stated, “The WFSA is delighted to announce Masimo as our first Global Impact Partner. We work together to improve patient care and access to safe anesthesia around the world.”
Dr Adrian Gelb, Chair of the WFSA’s Safety and Quality Committee and Professor of Anaesthesia and Perioperative Care at the UCSF School of Medicine, added, “It is essential that we make safe and affordable anesthesia and surgical care available to every patient in every country. Investment in national anesthesia plans, together with key stakeholders, will ensure that specific country needs are met most appropriately in order to make the biggest impact.”
“At Masimo, we believe that regardless of where you live or where you were born, access to quality healthcare that is dignified and safe – including safe, effective anesthesia and surgery – is a human right, not a privilege,” said Joe Kiani, Founder and CEO of Masimo. “We are delighted to be the first partner with the WFSA in bringing much-needed help, with Safe Anaesthesia – ASAP, to areas of the world blighted by needless deaths.”
Mr. Kiani added: “The new millennium goal is no longer to provide all of our people access to health care, but to provide all of our people access to health care that is systematically safe and dignified.”
@MasimoInnovates | #Masimo | @0X2020 | @wfsaorg | #WCA2016
Meara JG, Leather AJ, Hagander L et al. Global Surgery 2030: Evidence and solutions for achieving health, welfare, and economic development. Surgery. 2015 Jul;158(1):3-6.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential success of the ASAP. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Irene Paigah, 8588597001